Drug intelligence / Profile preview

90Y-DOTA-30F11

Development stage: Preclinical
Lead developer: Fred Hutchinson Cancer Research Institute
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

90Y-DOTA-30F11 is a radiopharmaceutical conjugate designed for radioimmunotherapy (RIT) of hematologic malignancies, specifically acute myeloid leukemia (AML). It consists of the rat monoclonal antibody 30F11, which targets the murine CD45 antigen (leukocyte common antigen), conjugated via the DOTA chelator to the beta-emitting radionuclide Yttrium-90 (90Y). CD45 is highly expressed on the surface of most nucleated hematopoietic cells and leukemic blasts, making it an ideal target for delivering radiation to the bone marrow and spleen while sparing non-hematologic organs. In preclinical murine models, 90Y-DOTA-30F11 has demonstrated superior therapeutic efficacy compared to 177Lu-labeled counterparts, providing dose-dependent survival benefits with transient myelotoxicity. The drug is primarily developed and studied by researchers at the Fred Hutchinson Cancer Research Center as part of a broader effort to optimize RIT conditioning regimens for hematopoietic cell transplantation.

Other names: 90Y-anti-CD45 RIT90Y-labeled anti-CD45 antibody

Targets

PTPRC (Receptor-type tyrosine-protein phosphatase C)

Beyond the preview

Go deeper on 90Y-DOTA-30F11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 90Y-DOTA-30F11.

Explore the full profile